Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial (2018)

Peer-Reviewed Study · Dicko A; Roh ME; Diawara H; Mahamar A; Soumare HM; Lanke K; Bradley J; Sanogo K; Kone DT; Diarra K; Keita S; Issiaka D; Traore SF; McCulloch C; Stone WJR; Hwang J; Müller O; Brown JM; Srinivasan V; Drakeley C; Gosling R; Bousema T · February 6, 2018

Dicko A et al., 2018-02-06: Phase 2 single-blind four-arm randomised trial in Bamako, Mali, in 80 G6PD-normal gametocyte carriers: three days of methylene blue 15 mg/kg/day added to dihydroartemisinin-piperaquine abolished mosquito infectivity by day 2, as did a single 0.25 mg/kg dose of primaquine, with similar haemoglobin changes and tolerability.

The dihydroartemisinin-piperaquine plus methylene blue (n=11) group had a median 100% (IQR 100 to 100) within-person reduction in mosquito infectivity on day 2, a larger reduction than was noted with dihydroartemisinin-piperaquine alone (n=12; -6·0%, IQR -126·1 to 86·9; p<0·0001).

Abstract

Dicko A et al., 2018-02-06: Phase 2 single-blind four-arm randomised trial in Bamako, Mali, in 80 G6PD-normal gametocyte carriers: three days of methylene blue 15 mg/kg/day added to dihydroartemisinin-piperaquine abolished mosquito infectivity by day 2, as did a single 0.25 mg/kg dose of primaquine, with similar haemoglobin changes and tolerability. Study type: phase 2, single-blind, four-arm randomised controlled trial, NCT02831023. N=80 males aged 5-50 with asymptomatic P. falciparum gametocytaemia, Bamako, Mali; 54 infectious at baseline. MB 15 mg/kg per day orally for 3 days with dihydroartemisinin-piperaquine; comparators SP-AQ alone, SP-AQ plus primaquine 0.25 mg/kg, DHA-piperaquine alone. Primary endpoint: median within-person percentage change in mosquito infectivity days 2 and 7 by membrane feeding. Funding: Bill & Melinda Gates Foundation and European Research Council (stated in the abstract). Conflicts not stated in retrieved abstract record. G6PD-normal participants only. Also filed as MTI-112 (claims C1, C10). Study type: randomized trial.